Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Background Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration.Case presentation We report a 65-year-old man diagnosed with s...
Saved in:
| Main Authors: | Michael B Atkins, Michael T Serzan, Princy N Kumar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000898.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic immune checkpoint inhibitor pneumonitis
by: Julie R Brahmer, et al.
Published: (2020-05-01) -
Co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus HKU1 (HCoV-HKU1)
by: Laszlo Madaras, et al.
Published: (2025-01-01) -
Correction: Chronic immune checkpoint inhibitor pneumonitis
Published: (2020-10-01) -
Lupus Pneumonitis Therapy Masks Coronavirus (COVID-19)
by: S. Soloway, et al.
Published: (2021-01-01) -
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
by: Giampaolo Tortora, et al.
Published: (2020-10-01)